Fig. 1: SPR analysis of SARS-CoV-2-specific TCRs binding to spike epitopes and epitope variants. | Nature Communications

Fig. 1: SPR analysis of SARS-CoV-2-specific TCRs binding to spike epitopes and epitope variants.

From: Structural assessment of HLA-A2-restricted SARS-CoV-2 spike epitopes recognized by public and private T-cell receptors

Fig. 1

a (upper) TCR RLQ3 at concentrations of 0.78, 1.56, 3.12, 6.25, 12.5, 25.0, 50.0, and 100 μM was injected over immobilized RLQ–HLA-A2 (1200 RU). (lower) Fitting curve for equilibrium binding that resulted in a KD of 32.9 μM. b (upper) TCR RLQ3 at concentrations of 3.12, 6.25, 12.5, 25.0, 50.0, 100, 200, and 400 μM was injected over immobilized T1006I–HLA-A2 (1200 RU). (lower) Fitting curve for equilibrium binding that resulted in a KD of 170 μM. c–e TCR RLQ3 at concentrations of 0.39, 0.78, 1.56, 3.12, 6.25, 12.5, 25.0, 50.0, and 100 μM was injected over immobilized MERS-RLT–HLA-A2 (1600 RU), HKU1-RLT–HLA-A2 (700 RU), NL63-RLA–HLA-A2 (700 RU). f (upper) TCR YLQ7 at concentrations of 0.39, 0.78, 1.56, 3.12, 6.25, 12.5, and 25.0 μM was injected over immobilized YLQ–HLA-A2 (300 RU). (lower) Fitting curve for equilibrium binding that resulted in a KD of 1.8 μM. g (upper) TCR YLQ7 at concentrations of 6.25, 12.5, 25.0, 50.0, 100, 200, and 400 μM was injected over immobilized P272L–HLA-A2 (2000 RU). (lower) Fitting curve for equilibrium binding that resulted in a KD of 116 μM. h–k TCR pYLQ7 at concentrations of 0.39, 0.78, 1.56, 3.12, 6.25, 12.5, 25, and 50 μM was injected over immobilized MERS-KLQ–HLA-A2, SARS-YLK–HLA-A2, HKU1-PLS–HLA-A2, and OC43-PLT–HLA-A2, respectively (500 RU).

Back to article page